



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket Nos. 71369.368 and PFI-016CIPDV)

In re Application of: Orlow et al.) Examiner: To Be Assigned
Serial No. 10/758,335) Group Art Unit: 1614
Filing Date: January 15, 2004)

For: METHODS AND COMPOSITIONS THAT AFFECT MELANOGENESIS

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below.

5/21/04
Date


Sarah Farris

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Dear Sir:

Prior to issuance of a first Office Action on the merits, please amend the above-referenced application as follows:

In the Specification:

On page 17, please delete the paragraph at lines 1-3 and replace it with the following paragraph:

Figure 18 is a graphic representation providing measurements of tyrosinase activity of extract from melan-a melanocytes incubated with U18666A. Control cells received no drug treatment, and test cells were treated with 300 μ M PTU, 10 μ M IBMX, or 2.5 μ M U18666A.

On page 17, please delete the paragraph at lines 4-6.

On page 81, please delete the paragraph at lines 13-15 and replace it with the following paragraph:

Results of the Western blot analysis show that the total amount of tyrosinase in the cell after exposure to U18666A is not significantly less than the control, untreated cell.